Oxygenta Pharmaceutical Ltd — Important, 26-05-2026: Company Update

Oxygenta Pharmaceutical Limited has submitted its Annual Secretarial Compliance Report for the financial year, confirming overall adherence to relevant regulatory provisions. A key point for investors is that the company's manufacturing license faced a temporary suspension for seven days. This action was taken due to violations of drug and cosmetics rules, indicating a period of operational non-compliance. The report emphasizes the company's general compliance status, with this specific issue being the notable deviation impacting operations.